Involvement of supraspinal and peripheral naloxonazine-insensitive opioid receptor sites in the expression of μ-opioid receptor agonist-induced physical dependence

European Journal of Pharmacology

Volumn 715, Issue 1-3, 2013, Pages 238-245

  Mori, Tomohisa ^a   Komiya, Sachiko ^a   Uzawa, Naoki ^a   Inoue, Koichi ^b   Itoh, Toshimasa ^a   Aoki, Shiyou ^a   Shibasaki, Masahiro ^a   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Fentanyl; Morphine; Naloxonazine; Naloxone methiodide; Oxycodone; Withdrawal syndrome

Indexed keywords

17 METHYLNALOXONE; FENTANYL; MORPHINE; NALOXONAZINE; OPIATE RECEPTOR; OXYCODONE;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; JUMPING; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NARCOTIC DEPENDENCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PTOSIS; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; TANDEM MASS SPECTROMETRY; TREMOR; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

FENTANYL; MORPHINE; NALOXONAZINE; NALOXONE METHIODIDE; OXYCODONE; WITHDRAWAL SYNDROME;

ANIMALS; FREE RADICALS; MALE; MICE; NALOXONE; PERIPHERAL NERVOUS SYSTEM; RECEPTORS, OPIOID, MU; SPINAL CORD; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 84885468752     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.05.015     Document Type: Article

References (29)

1. Beubler, E., Bukhave, K., Rask-Madsen, J., 1984. Colonic secretion mediated by prostaglandin E2 and 5-hydroxytryptamine may contribute to diarrhea due to morphine withdrawal in the rat. Gastroenterology 87, 1042-1048. (Pubitemid 14017071)
2. Cadet, P., 2004. Mu opioid receptor subtypes. Med. Sci. Monit. 10, MS28-32.
3. Chang, E.B., Brown, D.R., Field, M., Miller, R.J., 1984. An antiabsorptive basis for precipitated withdrawal diarrhea in morphine-dependent rats. J. Pharmacol. Exp. Ther. 228, 364-369. (Pubitemid 14190742)
4. Elliott, J., Smart, D., Lambert, D.G., Traynor, J.R., 1994. Characterisation of mu-opioid receptors on SH-SY5Y cells using naloxonazine and beta-funaltrexamine. Eur. J. Pharmacol. 268, 447-450.
5. Frederickson, R.C., Smits, S.E., 1973. Time course of dependence and tolerance development in rats treated with "slow release," morphine suspensions. Res. Commun. Chem. Pathol. Pharmacol. 5, 867-870.
6. Kamei, J., Ohsawa, M., Saitoh, A., Iwamoto, Y., Suzuki, T., Misawa, M., Nagase, H., Kasuya, Y., 1995. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes. J. Pharmacol. Exp. Ther. 274, 700-706.
7. Koga, Y, 1976. Induction of physical dependence in rats by short interval medication. Psychopharmacology (Berl) 50, 153-157.
8. Laska, J.F., Fennessy, M.R., 1976. Physical dependence in the rat induced by slow release morphine: dose-response, time course and brain biogenic amines. Clin. Exp. Pharmacol. Physiol. 3, 587-598.
9. Leppert, W., 2010. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv. Ther 27, 714-730.
10. Ling, G.S., MacLeod, J.M., Lee, S., Lockhart, S.H., Pasternak, G.W., 1984. Separation of morphine analgesia from physical dependence. Science 226 (4673), 462-464. (Pubitemid 14012817)
11. Majumdar, S., Grinnell, S., Le Rouzic, V., Burgman, M., Polikar, L., Ansonoff, M., Pintar, J., Pan, Y.X., Pasternak, G.W., 2011. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc. Natl. Acad. Sci. USA, 108; pp. 19778-19783.
12. Manfio, J.L., Santos, V.J., Lanchote, V.L, Santos, L.M., Carmona, M.J., Auler, J.O., Brum, L.J., Donaduzzi, CM., Santos, S.R., 2011. Development and validation of an HPLC/MS/MS method for the determination of sufentanil and morphine in human plasma. J. AOAC. Int. 94, 136-142.
13. Minami, K., Hasegawa, M., Ito, H., Nakamura, A., Tomii, T, Matsumoto, M., Orita, S., Matsushima, S., Miyoshi, T, Masuno, K., Torii, M., Koike, K., Shimada, S., Kanemasa, T., Kihara, T., Narita, M., Suzuki, T., Kato, A., 2009. Morphine, oxycodone, fentanyl exhibit different analgesic profiles in mouse pain model. J. Pharmacol. Sci. 111, 60-72.
14. Matsuzawa, S., Suzuki, T., Misawa, M., 2000. Involvement of mu-opioid receptor in the salsolinol-assocxiated place preference in rats exposed to conditioned fear stress. Alcohol Clin. Exp. Res 24, 366-372. (Pubitemid 30170215)
15. Mori, T., Ito, S., Matsubayashi, K., Sawaguchi, T., 2007. Comparison of nitric oxide synthase inhibitors, phospholipase A2 inhibitor and free radical scavengers as attenuators of opioid withdrawal syndrome. Behav. Pharmacol. 18, 725-729. (Pubitemid 350076429)
16. Nakamura, A., Hasegawa, M., Ito, H., Minami, K., Koike, K., Habu-Tomita, N., Nanba, K., Hamaguchi, K., Noshi, E., Hashimoto, H., Nishino, I., Okabayashi, Y, Koyabu, K., Kihara, T., Iwamoto, Y, Inoue, Y, Narita, M., Suzuki, T, Kato, A., 2011. Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine and fentanyl. J. Pain Palliat. Care Pharmacother. 25, 318-334.
17. Narita, M., Imai, S., Itou, Y, Yajima, Y, Suzuki, T, 2002. Possible involvement of mu1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Life Sci. 70, 2341-2354. (Pubitemid 34261045)
18. Narita, M., Imai, S., Ozaki, S., Suzuki, M., Narita, M., Suzuki, T., 2003. Reduced expression of a novel mu-opioid receptor (MOR) subtype MOR-1B in CXBK mice: implications of MOR-1B in the expression of MOR-mediated responses. Eur. J. Neurosci. 18, 3193-3198. (Pubitemid 38031045)
19. Pasternak, G.W., 1993. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16, 1-18. (Pubitemid 23028493)
20. Salem, A., Hope, W., 1998. A study on seasonal variation in the development of morphine dependence in rats. J. Pharmacol. Toxicol. Methods 40, 151-157. (Pubitemid 29142482)
21. Slatkin, N., Thomas, J., Lipman, A.G., Wilson, G., Boatwright, M.L., Wellman, C, Zhukovsky, D.S., Stephenson, R., Portenoy, R., Stambler, N., Israel, R., 2009. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patient. J. Support Oncol. 7, 39-46.
22. Suzuki, T., Hayashi, Y, Misawa, M., 1992. The role of mu1 receptor in physical dependence on morphine using the mu receptor deficient CXBK mouse. Life Sci. 50, 849-856.
23. Suzuki, T., Mori, T., Tsuji, M., Misawa, M., Nagase, H., 1995. Discriminative stimulus properties of morphine mediated by mu 1-opioid receptors. Eur. J. Pharmacol. 284, 195-198.
24. Suzuki, T., Shimada, M., Yoshii, T., Uesugi, J., Yanaura, S., 1983. Development of physical dependence on and tolerance to morphine in rats treated with morphine-admixed food. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 7, 63-71. (Pubitemid 13081152)
25. Suzuki, T., Tsuji, M., Mori, T., Misawa, M., Nagase, H., 1997. Involvement of delta 1 and delta 2 opioid receptor subtypes in the development of physical dependence on morphine in mice. Pharmacol. Biochem. Behav. 57, 293-299. (Pubitemid 27261424)
26. Teiger, D.G., 1974. Induction of physical dependence on morphine, codeine and meperidine in the rat by continuous infusion. J. Pharmacol. Exp. Ther. 190, 408-415.
27. Wolozin, B.L., Pasternak, G.W., 1981. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc. Natl. Acad. Sci. USA, 78; pp. 6181-6185. (Pubitemid 12174847)
28. Woodcock, J., 2009. A difficult balance-pain management, drug safety, and the FDA. N. Engl. J. Med. 361, 2105-2107.
29. World Health Organization, 1996. Cancer Pain Relief, 2nd ed. WHO, Geneva.